PTC Therapeutics PTCT Debt Issuance Cost Amortization
Debt Issuance Cost Amortization at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCosts.
The official record: PTC Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about PTC Therapeutics's debt issuance cost amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is PTC Therapeutics's debt issuance cost amortization?
- PTC Therapeutics (PTCT) reported debt issuance cost amortization of $305K in Q1 2026.
- How has PTC Therapeutics's debt issuance cost amortization changed year-over-year?
- PTC Therapeutics's debt issuance cost amortization increased by 2.0% year-over-year, from $299K to $305K.
- What is the long-term trend for PTC Therapeutics's debt issuance cost amortization?
- Over 4 years (2021 to 2025), PTC Therapeutics's debt issuance cost amortization has grown at a -9.9% compound annual growth rate (CAGR), from $1.85M to $1.22M.
- What does debt issuance cost amortization mean?
- Non-cash amortization of capitalized costs incurred to issue debt (underwriting fees, legal costs, SEC filing fees).